CIK 0001397702
SILK Silk Road Medical Inc
Insider trading from SEC Form 4. Last filing Jun 21, 2024.
In brief
Silk Road Medical Inc (SILK) has 14 SEC Form 4 filings on file from 10 insiders, the latest filed on Jun 21, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
8 open-market trades have been scored at SILK. The newest: Kevin J. Ballinger (director) bought $199k of stock on Mar 5, 2024, filed Mar 7, 2024, scored 37 (weak). 5 insiders sold within 14 days of each other around Mar 5, 2024.
6 Form 144 notices of planned sales are on file, the latest filed Mar 5, 2024.
Last 90 days
Signals
Open-market buys and sells at Silk Road Medical Inc, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Kevin J. Ballinger director buy | $199k 11,700 shares | +192% | - | |
| 48Moderate | Lucas W. Buchanan COO/CFO sell | $170k 9,877 shares | -2% | - | |
| 40Moderate | Andrew S. Davis Chief Commercial Officer sell | $94k 5,481 shares | -2% | - | |
| 36Weak | Marie L. Jones VP, Finance and CAO sell | $45k 2,602 shares | -3% | - | |
| 36Weak | Kevin M Klemz EVP/Chief Legal Officer/Sec. sell | $43k 2,497 shares | -1% | - | |
| 38Weak | Richard Ruedy EVPClin&Reg.Affairs&QA sell | $65k 3,800 shares | -2% | - | |
| 18Weak | Richard Ruedy EVPClin&Reg.Affairs&QA sell | $67k 3,000 shares | -2% | - | |
| 15Weak | Marie L. Jones CAO and VP, Finance sell | $4,334 656 shares | -1% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 5, 2024 | Buchanan Lucas W. Officer | 9,877 0.03% of outstanding | $170k | Mar 5, 2024 | none |
| Mar 5, 2024 | Davis Andrew S. Officer | 5,481 0.01% of outstanding | $94k | Mar 5, 2024 | none |
| Mar 5, 2024 | Klemz Kevin M Officer | 2,497 0.01% of outstanding | $43k | Mar 5, 2024 | none |
| Mar 5, 2024 | Ruedy Richard Officer | 3,800 0.01% of outstanding | $65k | Mar 5, 2024 | $67k |
| Feb 29, 2024 | Ruedy Richard Officer | 3,000 0.01% of outstanding | $67k | Feb 29, 2024 | none |
| Nov 6, 2023 | Rogers Erica J. Former Officer and Director | 22,733 0.06% of outstanding | $198k | Nov 6, 2023 | none |
Transactions
Every row filed, 19 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2024 | Kevin J. Ballinger director | AGrant or award Common Stock | +5,859 | $0.00 | $0 | 23,666 | Jun 21, 2024 |
| Jun 18, 2024 | Tanisha Carino director | AGrant or award Common Stock | +5,859 | $0.00 | $0 | 11,396 | Jun 21, 2024 |
| Jun 18, 2024 | Tony M. Chou director | AGrant or award Common Stock | +5,859 | $0.00 | $0 | 85,251 | Jun 21, 2024 |
| Jun 18, 2024 | Rick D Anderson director | AGrant or award Common Stock | +5,859 | $0.00 | $0 | 11,966 | Jun 21, 2024 |
| Mar 5, 2024 | Kevin J. Ballinger director | POpen-market purchase Common Stock | +11,700 | $16.99 | $199k | 17,807 | Mar 7, 2024 |
| Mar 5, 2024 | Richard Ruedy EVPClin&Reg.Affairs&QA | SOpen-market sale Common Stock | -3,800 | $17.17 | $65k | 205,711 | Mar 5, 2024 |
| Mar 1, 2024 | Chas McKhann Chief Executive Officer | AGrant or award Common Stock | +110,313 | $0.00 | $0 | 722,396 | Mar 5, 2024 |
| Mar 1, 2024 | Kevin M Klemz EVP/Chief Legal Officer/Sec. | AGrant or award Common Stock | +42,818 | $0.00 | $0 | 167,691 | Mar 5, 2024 |
| Mar 1, 2024 | Marie L. Jones VP, Finance and CAO | AGrant or award Common Stock | +24,555 | $0.00 | $0 | 79,496 | Mar 5, 2024 |
| Mar 1, 2024 | Andrew S. Davis Chief Commercial Officer | AGrant or award Common Stock | +62,201 | $0.00 | $0 | 293,254 | Mar 5, 2024 |
| Mar 1, 2024 | Lucas W. Buchanan COO/CFO | AGrant or award Common Stock | +74,954 | $0.00 | $0 | 510,802 | Mar 5, 2024 |
| Mar 5, 2024 | Kevin M Klemz EVP/Chief Legal Officer/Sec. | SOpen-market sale Common Stock | -2,497 | $17.17 | $43k | 165,194 | Mar 5, 2024 |
| Mar 5, 2024 | Marie L. Jones VP, Finance and CAO | SOpen-market sale Common Stock | -2,602 | $17.17 | $45k | 76,894 | Mar 5, 2024 |
| Mar 5, 2024 | Andrew S. Davis Chief Commercial Officer | SOpen-market sale Common Stock | -5,481 | $17.17 | $94k | 287,773 | Mar 5, 2024 |
| Mar 5, 2024 | Lucas W. Buchanan COO/CFO | SOpen-market sale Common Stock | -9,877 | $17.17 | $170k | 500,925 | Mar 5, 2024 |
| Feb 29, 2024 | Richard Ruedy EVPClin&Reg.Affairs&QA | SOpen-market sale Common Stock10b5-1 | -3,000 | $22.25 | $67k | 170,837 | Mar 4, 2024 |
| Mar 1, 2024 | Richard Ruedy EVPClin&Reg.Affairs&QA | AGrant or award Common Stock10b5-1 | +38,674 | $0.00 | $0 | 209,511 | Mar 4, 2024 |
| Nov 2, 2023 | Chas McKhann Chief Executive Officer | AGrant or award Common Stock | +612,083 | $0.00 | $0 | 612,083 | Nov 3, 2023 |
| Oct 27, 2023 | Marie L. Jones CAO and VP, Finance | SOpen-market sale Common Stock | -656 | $6.61 | $4,334 | 54,941 | Oct 30, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Rick D Andersondirector
- Kevin J. Ballingerdirector
- Lucas W. BuchananCOO/CFO
- Tanisha Carinodirector
- Tony M. Choudirector
- Andrew S. DavisChief Commercial Officer
- Marie L. JonesVP, Finance and CAO
- Kevin M KlemzEVP/Chief Legal Officer/Sec.
- Chas McKhannChief Executive Officer
- Richard RuedyEVPClin&Reg.Affairs&QA
Questions about SILK
Answered from the filings on this page, as of the latest one.
Are insiders buying SILK?
No. In the last 90 days no insider at Silk Road Medical Inc bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade SILK on the open market?
Kevin J. Ballinger (director) bought $199k of SILK on Mar 5, 2024 and filed the Form 4 on Mar 7, 2024. InsiderTell scored 37 (weak).
How many insiders file Form 4 at Silk Road Medical Inc?
10 people have filed a Form 4 at Silk Road Medical Inc, among them Rick D Anderson (director), Kevin J. Ballinger (director), Lucas W. Buchanan (COO/CFO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.